





## ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK (CCP-UK) CASE REPORT FORM GUIDANCE FRONT PAGE 1 of 4

#### v9.8 16OCT2020

#### **DESIGN OF THE CCP-UK CASE REPORT FORM (CRF)**

This CRF is divided into a "ADMISSION" form (4 pages), a "DAILY" form (2 pages) for daily clinical and laboratory and data, an "OUTCOME" form (5 pages) and a "WITHDRAWAL" form (1 page).

#### **HOW TO USE THIS CRF**

The CRF is designed to complement the **Tier** of activity that a site has capacity and capability to work to. This is likely to vary over the course of an outbreak. The decision on which **Tier** to use is up to the Local Principal Investigator. All high-quality data is valuable for analysis.

Data can be collected as Tier Zero activity without consent including retrospectively and from deceased cases.

#### **IMPORTANT CHANGES FOR SECOND WAVE OF COVID-19**

Tier Zero will only include proved (positive test) COVID-19/ SARS-COV-2 cases and ANY admission following proved COVID-19/ SARS-COV-2 in the past 21 days regardless of setting of test (community or hospital tests).

Tiers 1 and 2 for now will only apply to patients with *re-infection, co-infection (flu/RSV)* or *inflammation (MIS-A/MIS-C)*. Ideally, data and samples will be collected with consent using Tier 2 of the protocol schedule.

Consent <u>must</u> be obtained for any biological sampling at Tier 1 and Tier 2.

Tier	
7ero	

For collection of data without consent from any case; current, past and deceased.

Please complete the **ADMISSION CRF** and **DAILY CRF** for the first day of hospital admission (day 1), the **DAILY CRF** again for the first day of any ICU admission, then the **INTERIM OUTCOME CRF** at day 28, discharge or death (whichever occurs first), and **FINAL OUTCOME** when known.

N.B. For patients receiving **Remdesivir** (RDV), please complete an extra **DAILY CRF** for **first day** that the drug is dosed and for day 14 after drug initiation (if patient remains admitted). **Collection of this data is requested by the CMOs in all nations.** 

OR

For sites where caseload or facilities limit research capacity to deliver planned Tier 1 or Tier 2 activity.

Tier 1 & 2

Tier 1- For sites where facilities limit research capacity to deliver Tier 2 activity or where consent is only for single timepoint biological sampling.

Tier 2- For sites with available resources to deliver Tier 2 activity per the protocol schedule and then with consent for multiple timepoint biological sampling.

For these tiers please complete the **ADMISSION CRF** and **DAILY CRF** for the first day of hospital admission (day 1), the **DAILY CRF** for the third (d3), sixth (d6) and ninth (d9) days, the **DAILY CRF** again for the first day of any ICU admission, and then the **INTERIM OUTCOME CRF** at day 28, discharge or death (whichever occurs first), and **FINAL OUTCOME** when known.

N.B. For patients receiving **Remdesivir** (RDV), please complete an extra **DAILY CRF** for **first day** that such a drug is dosed and for day 14 after drug initiation (if patient remains admitted). **Collection of this data is requested by the CMOs in all nations.** 



PARTICIPANT ID I \_\_\_ I I \_\_\_ I

Example: R B S 2 5 -- 0 0 1 6
On each page above here write site code & participant number as per this

#### **CASE REPORT FORMS**

#### FRONT PAGE 2 of 4

#### **GENERAL GUIDANCE**

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date or deceased after admission.
- Participant Identification Numbers consist of a 5-digit CPMS / ODS site code and a 4-digit participant number. You should obtain a site code by contacting your local R&D office or <a href="CCP@liverpool.ac.uk">CCP@liverpool.ac.uk</a>
- Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of
  a single site recruiting participants on different wards, or where it is otherwise difficult to assign
  sequential numbers, it is acceptable to assign numbers in blocks. E.g. Ward X will assign numbers
  from 0001 onwards and Ward Y will assign numbers from 5001 onwards. Enter the Participant
  Identification Number at the top of every page.
- Please generate a new subject ID for each re-admission
- CRF data should be entered to the central database at <a href="https://ncov.medsci.ox.ac.uk">https://ncov.medsci.ox.ac.uk</a>
- REDCap registration access is obtained by contacting <u>CCP.REDCap@liverpool.ac.uk</u>
- Please contact us at <a href="mailto:CCP.REDCap@liverpool.ac.uk">CCP.REDCap@liverpool.ac.uk</a> for help with database problems.

#### **RULES DEFINING DAYS**

- 1. Day of Admission = Day of Admission regardless, e.g. even if admitted 2 months ago for a broken hip.
- 2. For Community Acquired COVID-19 i.e. admitted with symptoms consistent with COVID-19, day 1 = first 24 hours of admission.
- 3. For those who are already admitted for any other reason and who subsequently test positive, day 1 = day the positive COVID-19 test was collected.
- 4. Rules 2 and 3 are important but we recognise that start of biological sampling for Tier 1 and 2 may be deferred or delayed for several reasons, e.g. due to a delay in the COVID-19 result being reported. If this happens, please take the d1 sample set as soon as possible and then d3 and d9 according to schedule, or as close as possible.
- 5. For Tier Zero date of enrolment is date on which the act of data collection started (no consent). For Tier 1 & 2 date of enrolment is date of consent.

Patients with confirmed Covid-19 with any of the following syndromes should be recruited to tiers 1 or 2:

- **Re-infection**. The patient had Covid-19 more than 21 days ago:
  - 1. See criteria for identifying suspected re-infection on page 4.
  - 2. If you think a patient has suspected re-infection, please call 0300 365 4423to discuss.
- **Co-infection**. The patient has **confirmed co-infection** with:
  - 1. Influenza A or B virus; or,
  - 2. Respiratory syncytial virus (RSV).
- Clinical suspicion of Multisystem Inflammatory Syndrome in Adults (MIS-A) or Children (MIS-C) ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK CCP-UK Case Report Form v9.8 16OCTOBER2020

#### **CASE REPORT FORMS**

#### **FRONT PAGE 3 of 4**

- Complete every line of every section, except for where the instructions say to skip a section based on certain responses.
- $\triangleright$  Selections with square boxes ( $\square$ ) are single selection answers (choose one answer only). Selections with circles ( $\mathbf{O}$ ) are multiple selection answers (choose as many answers as are applicable).
- Some fields are considered URGENT AND ESSENTIAL. These are marked BOLD AND UNDERLINED IN ALL CIRCUMSTANCES PLEASE PRIORITISE THESE DATA POINTS FOR URGENT UPLOAD.
- Mark 'N/K' for any results of laboratory values that are not known or not available.
- Avoid recording data outside of the dedicated areas. Sections are available for recording additional information.
- ➤ We recommend writing clearly in black ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) when you choose the corresponding answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- In the case of a participant transferring between study sites, such as to a Nightingale Hospital, or other surge facility, it is preferred to maintain the same Participant Identification Number across the sites. When this is not possible a new Participant Identification Number should be assigned, the transferred participant will be linked by their identifiable data.
- ➤ Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- These three FRONT PAGES do not need to be retained.
- > DO NOT SEND CRFs to anyone by email or post.
- See the training guide on how to send consent to <a href="CCP@liverpool.ac.uk">CCP@liverpool.ac.uk</a> using [SECURE] encryption
- > The Dalhousie University Clinical Frailty Score is provided below for your reference.

#### Clinical Frailty Scale\*



I Very Fit – People who are robust, active, energetic and motivated. These people commonly exercise regularly. They are among the fittest for their age.



2 Well – People who have **no active disease** symptoms but are less fit than category 1. Often, they exercise or are very **active occasionally**, e.g. seasonally.



3 Managing Well – People whose medical problems are well controlled, but are not regularly active beyond routine walking.



4 Vulnerable – While not dependent on others for daily help, often symptoms limit activities. A common complaint is being "slowed up", and/or being tired during the day.



5 Mildly Frail – These people often have more evident slowing, and need help in high order IADLs (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework.



6 Moderately Frail – People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing.



7 Severely Frail – Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within  $\sim$  6 months).

8 Very Severely Frail – Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.



9. Terminally III - Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently frail.</p>

#### Scoring frailty in people with dementia

The degree of frailty corresponds to the degree of dementia. Common symptoms in mild dementia include forgetting the details of a recent event, though still remembering the event itself, repeating the same question/story and social withdrawal.

In **moderate dementia**, recent memory is very impaired, even though they seemingly can remember their past life events well. They can do personal care with prompting.

In severe dementia, they cannot do personal care without help.

 I. Canadian Study on Health & Aging, Revised 2008.
 K. Rockwood et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-495.

© 2007-2009. Version 1.2. All rights reserved. Geriatric Medici Research, Dalhousie University, Halifax, Canada. Permission gra





PARTICIPANT ID I \_\_ | I -- | \_\_ | I \_\_ | I \_\_ | I \_\_ |

#### CASE REPORT FORMS

**FRONT PAGE 4 of 4** 

#### **GENERAL GUIDANCE**

**Definitions:** 

#### **INFLAMMATION** - Children and adolescents

WHO preliminary criteria Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19

Children and adolescents 0–19 years of age with fever  $\geq$  3 days

**AND** any two of the following:

- 1. Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet).
- 2. Hypotension or shock.
- 3. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP),
- 4. Evidence of coagulopathy (by PT, PTT, elevated d-Dimers).
- 5. Acute gastrointestinal problems (diarrhoea, vomiting, or abdominal pain).

#### AND

Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin.

#### AND

No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes.

#### AND

Evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with COVID-19

#### **INFLAMMATION - Adults**

We deliberately do not give criteria to avoid selection bias. Adults with an inflammatory should to be identified at clinical discretion.

If you think a patient meets these criteria or wish to discuss, please call 0300 365 4423.

#### **RE-INFECTION**

To be considered a suspected Covid-19 re-infection the patient should meet one prior Covid-19 criterion and one timing criterion. If you think a patient meets these criteria or wish to discuss, please call 0300 365 4423.

#### Prior Covid-19 criteria

- A positive test for virus (PCR or antigen) or antibodies, in the community or in a hospital. Evidence of this can be from the patient's own recollection, or from medical records.
- Patient-reported symptoms strongly suggestive of Covid-19, including cough, fever and altered taste/smell

#### Timing criteria

- If the patient was previously hospitalised with Covid-19, they must be more than 21 days from discharge from acute hospital (not including rehabilitation hospital).
- If the patient was not hospitalised but had symptoms of Covid-19, they must be more than 21 days from last symptoms.
- If the patient did not have symptoms, they must be more than 21 days from their last positive Covid-19 test.

ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK CCP-UK Case Report Form v9.8 16OCTOBER2020



PARTICIPANT ID I	- 11	11	11	11	I I	1 1	- 1 1	11	- 1

## ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK ADMISSION FORM page 1 of 4

**Date of enrolment** [ D ][ D ]/[ M ][ M ]/[ 2 ][ O ][ Y ][ Y ] **Site Location CLINICAL INCLUSION CRITERIA** Proven infection with pathogen of Public Health Interest: ☐ YES ☐ NO N.B. For acute covid-19, please only collect data from proven (laboratory test-positive) people. OR Adult or child who meets Case Definition for Multisystem Inflammatory Syndrome (MIS-C/MIS-A): ☐ YES ☐ NO N.B. This group should be recruited regardless of covid-19 test as this syndrome can occur after mild disease in the community which has gone untested. **DEMOGRAPHICS** Sex at Birth: ☐ Male ☐ Female ☐ Not specified Date of birth [ □ ][ □ ]/[ M ][ M ]/[ Y ][ Y ][ Y ][ Y ] If date of birth is Not Known (N/K) record Age: [ ][ ]years OR [ ][ ]months Postcode: [\_\_][\_\_][\_\_] [\_\_] England & Wales NHS number , Scotland CHI: [\_\_][\_\_] [\_\_] [\_\_][\_\_] [\_\_][\_\_] NB Northern Ireland Health & Care Number is not being collected at this time Ethnic group (check all that apply): OArab OBlack OEast Asian OSouth Asian OWest Asian OLatin American OWhite OAboriginal/First Nations OOther: □N/K Employed as a Healthcare Worker? ☐YES ☐NO ☐N/K Pregnant? ☐ YES ☐ NO ☐ N/K If YES: Gestational weeks assessment: [\_\_\_][\_\_\_] weeks POST PARTUM (within six weeks of delivery)? ☐YES ☐NO or ☐N/K (skip this section - go to INFANT) Pregnancy Outcome: □Live birth □Still birth Delivery date: [\_D\_][\_D\_]/[\_M\_][\_M\_]/[\_2\_][\_0\_][\_Y\_][\_Y\_] Has infant(s) been tested for Mother's infection? ☐YES ☐NO ☐N/K If YES: ☐Positive ☐Negative IF POSITIVE PLEASE COMPLETE A SEPARATE CASE REPORT FORM FOR THE INFANT(s) INFANT – Less than 1 year old? □YES □NO (skip this section) Birth weight: [ ]. [ ]kg □N/K Gestational: ☐ Term birth (≥37wk GA) ☐ Preterm birth (<37wk GA) if <37wk Estimated gestation \_\_\_\_\_weeks ☐N/K Breastfed? ☐YES ☐NO ☐N/K If YES: ☐Currently breastfed ☐Breastfeeding discontinued ☐N/K **VACCINATION STATUS** Covid-19 vaccine ☐YES ☐NO ☐N/K date if known :  $[_D][_D]/[_M][_M]/[_2][_0][_Y][_Y]$ 

date if known :  $[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]$ 

2020/21 seasonal influenza vaccine ☐YES ☐NO ☐N/K



Fatigue / Malaise

(Ageusia)

Shortness of breath (Dyspnoea)

Disturbance or loss of taste

**ADMISSION FORM** 

#### PARTICIPANT ID I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I

Page 2 of 4

ONSET AND ADMISSION					
Date of first/earliest symptom: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] OR    Admission date at this facility: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]  Is the patient being readmitted with Covid-19? (Please only add re-admission episodes for COVID patients remaining or new					
positive COVID test- Please assi	ign new subject ID) □YES □N	IO ∐N/K			
Previous participant ID : I_I	II II	II II □ NK			
Please provide reason for read	mission:		□n/k		
definition met) more than 21 d	ays prior to this new laboratory	ven (PCR or antibody test) or high proven covid-19 infection   for biological sampling, ideally at	YES □NO □N/K		
Is this a NIGHTINGALE or other S	SURGE FACILITY DYES DNO	□n/k			
Transfer from other facility?	/FS-other facility is a study site	☐YES-other facility is not a study	sita ONO ON/K		
-		•	Site LIVO LIVIK		
If YES: Name of transfer facility	<u>:</u>				
If YES: Admission date at pre	vious facility (DD/MM/YYYY): [	D_][_D_]/[_M_][_M_]/[_2_][_0_	][_Y_][_Y_]		
If YES-Study Site: Participant	ID # at previous facility: $I\_\_I$ $I\_$		I_II_I		
OR □Same as above					
VITAL SIGNS AT HOSPITAL ADM	MISSION -first available data at pr	esentation/Admission to the facility	<i>'</i> .		
(This section should refer to data	from the date of admission to th	nis facility)			
Temperature: [_ ][_ ].[_ ]°C	HR: [_ ][_ ][_ ]beats per	minute RR: [_ ][_ ]breaths	s per minute		
Systolic BP: [_ ] [_ ] [_ ]mmHg	Diastolic BP: [_ ][_ ][_ ]mm	Hg Severe dehydration: □YES	□no □n/k		
Sternal capillary refill time >2se			-		
Oxygen saturation: [ ][ ][	-	Ovygen therany DN/K			
		Skygen therapy DN/K			
SIGNS AND SYMPTOMS- Thi	s section should refer to the sta	rt of the COVID episode			
History of fever	□YES □NO □N/K	Lower chest wall indrawing	□YES □NO □N/K		
Cough	□YES □NO □N/K	Headache	□YES □NO □N/K		
with sputum production	□YES □NO □N/K	Altered	□YES □NO □N/K		
bloody sputum/haemoptysis	□YES □NO □N/K	consciousness/confusion Seizures	Dyra Dyra Dyra		
Sore throat	□YES □NO □N/K	Abdominal pain	□YES □NO □N/K		
Runny nose (Rhinorrhoea)	□YES □NO □N/K	Vomiting / Nausea	□YES □NO □N/K □YES □NO □N/K		
Ear pain	□YES □NO □N/K	Diarrhoea	□YES □NO □N/K □YES □NO □N/K		
Wheezing	□YES □NO □N/K	Conjunctivitis	□YES □NO □N/K		
Chest pain	□YES □NO □N/K	Skin rash	□YES □NO □N/K		
Muscle aches (Myalgia)	□YES □NO □N/K	Skin ulcers	□YES □NO □N/K		
Joint pain (Arthralgia)	□YES □NO □N/K	Lymphadenopathy	□YES □NO □N/K		

Bleeding (Haemorrhage)

(Anosmia)

None

If Bleeding: specify site(s):

Disturbance or loss of smell

□YES □NO □N/K



**ADMISSION FORM** 

Chronic neurological disorder

Chronic hematologic disease

Malignant neoplasm

#### PARTICIPANT ID I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I I\_\_\_I

Other relevant risk factor

□YES □NO □N/K

Page 3 of 4

Smoking □YES □Never smoked □Former smoker □N/K

CO-MORBIDITIES (existing)	prior to admission)		
Chronic cardiac disease, including congenital heart disease. (not hypertension)	□YES □NO □N/K	Obesity (as defined by clinical staff)	□YES □NO □N/K
Hypertension (physician diagnosed)	□YES □NO □N/K	Diabetes and Type	□YES □NO □1 □2 □N/K
Chronic pulmonary disease (not asthma)	□YES □NO □N/K	Diabetes (any) with complications	□YES □NO □N/K
Asthma (physician diagnosed)	□YES □NO □N/K	Diabetes (any) without complications	□YES □NO □N/K
Chronic kidney disease	□YES □NO □N/K	Rheumatologic disorder	□YES □NO □N/K
Moderate / severe liver disease	□YES □NO □N/K	Dementia	□YES □NO □N/K
Mild liver disease	□YES □NO □N/K	Malnutrition	□YES □NO □N/K

□YES □NO □N/K

□YES □NO □N/K

□YES □NO □N/K

AIDS / HIV	□YES □NO □N/K	If yes, specify						
Is the patient thought to be	a member of a CLINIC	ALLY EXTREMELY VULNERABLE GROUP						
Solid organ transplant recipients:	□YES □NO □N/K							
People with specific cancers:	res □no □n/k							
<ul> <li>people with cancer who ar</li> </ul>	e undergoing active chemo	therapy						
<ul> <li>people with lung cancer wl</li> </ul>	ho are undergoing radical ra	adiotherapy						
<ul> <li>people with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment</li> </ul>								
<ul> <li>people having immunother</li> </ul>	<ul> <li>people having immunotherapy or other continuing antibody treatments for cancer</li> </ul>							
<ul> <li>people having other target or PARP inhibitors</li> </ul>	people nating out at a getter than a continue to the continue of the continue							
<ul> <li>people who have had bone immunosuppression drugs</li> </ul>		plants in the last 6 months, or who are still taking						
People with <u>severe</u> respiratory conditions including all cystic fibrosis, severe asthma requiring daily oral steroid or injectable maintenance therapy and severe chronic obstructive pulmonary requiring oxygen (COPD): $\Box$ YES $\Box$ NO $\Box$ N/K								
People with rare diseases and inborn errors of metabolism that significantly increase the risk of infections (such as Severe combined immunodeficiency (SCID), homozygous sickle cell): $\Box$ YES $\Box$ NO $\Box$ N/K								
People on immunosuppression therapies sufficient to significantly increase risk of infection: ☐YES ☐NO ☐N/K								
Women who are pregnant with significant heart disease, congenital or acquired: ☐YES ☐NO ☐N/K								



**ADMISSION FORM** 

PARTICIPANT ID	1 1	1 1	1 1	1 1	1 1		1 1	1 1	I I

Page 4 of 4

PRE-ADMISSION MEDICATION Were any of the follo	owing taken within 14 days of admission?
Immunosuppressant e.g. oral (not inhaled) corticosteroids	Angiotensin converting enzyme inhibitors (ACEI)?
(not low dose hydrocortisone) □YES □NO □N/K	□YES □NO □N/K
Anti-infectives for this illness episode prior to admission?	Angiotensin II receptor blockers (ARBs)? □YES □NO □N/K
□YES □NO □N/K If yes, specify:	Non-steroidal anti-inflammatory (NSAID)? ☐YES ☐NO ☐N/K
CLINICAL FRAILTY SCORE	
With reference to the Dalhousie University Clinical F	railty Score (see guidance page 3 of complete CRF)
Clinical Frailty Score	[] value 1 to 9 or □N/K
CURRENT MEDICATION ON ADMISSION	
Record medication the patient is currently taking or	has taken within the past 14 days
Medication name (generic name preferred):	



PARTICIPANT ID I	1.1	1.1	1.1	1.1	I I	1.1	1.1	1.1	- 1
FAITHCIFAITH	1 1	1 1	1 1					1 1	

## ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK REINFECTION FORM PAGE 1 OF 1

SUSPECTED RE-INFECTION WITH COVID-19: DETAILS OF PREVIOUS INFECTION	
Did the patient have a positive PCR (virus) test for SARS-CoV-2?	□YES □NO □N/K
If yes, enter date of positive test: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]	
Did the patient have a positive antigen (virus) test for SARS-CoV-2?	□YES □NO □N/K
If yes, enter date of positive test: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]	
Did the patient have a positive serology (antibody) test for SARS-CoV-2?	□YES □NO □N/K
If yes, enter date of positive test: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]	
Symptom onset date of first/earliest symptom for previous infection:  [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]	
OR LI Asymptomatic	

SIGNS AND SYMPTOMS for	PREVIOUS COVID-19 episod	e	
History of fever	□YES □NO □N/K	Lower chest wall indrawing	□YES □NO □N/K
Cough	□YES □NO □N/K	Headache	□YES □NO □N/K
with sputum production	□YES □NO □N/K	Altered consciousness/confusion	□YES □NO □N/K
bloody sputum/haemoptysis	□YES □NO □N/K	Seizures	□YES □NO □N/K
Sore throat	□YES □NO □N/K	Abdominal pain	□YES □NO □N/K
Runny nose (Rhinorrhoea)	□YES □NO □N/K	Vomiting / Nausea	□YES □NO □N/K
Ear pain	□YES □NO □N/K	Diarrhoea	□YES □NO □N/K
Wheezing	□YES □NO □N/K	Conjunctivitis	□YES □NO □N/K
Chest pain	□YES □NO □N/K	Skin rash	□YES □NO □N/K
Muscle aches (Myalgia)	□YES □NO □N/K	Skin ulcers	□YES □NO □N/K
Joint pain (Arthralgia)	□YES □NO □N/K	Lymphadenopathy	□YES □NO □N/K
Fatigue / Malaise	□YES □NO □N/K	Bleeding (Haemorrhage)	□YES □NO □N/K
Shortness of breath (Dyspnoea)	□YES □NO □N/K	If Bleeding: specify site(s):	
Disturbance or loss of taste (Ageusia )	□YES □NO □N/K	Disturbance or loss of smell (Anosmia)	□YES □NO □N/K
		None	
			□YES □NO □N/K
TREATMENT: During the previous	episode, was the patient:		
Admitted to hospital:	□YES □NO □N/K	Treated with:	
Treated with oxygen:	□YES □NO □N/K	Dexamethasone	□YES □NO □N/K
Admitted to HDU/ICU:	□YES □NO □N/K	Any other steroid	□YES □NO □N/K
Receive invasive ventilation:	□YES □NO □N/K	Tocilizumab	□YES □NO □N/K
Receive extracorporeal		Remdesivir	□YES □NO □N/K
membrane oxygenation (ECMO)	□YES □NO □N/K	Convalescent plasma	□YES □NO □N/K
		Lopinavir/Ritonavir	□YES □NO □N/K
		Interferon	□YES □NO □N/K
		Chloroquine/Hydroxychloroquine	□YES □NO □N/K



PARTICIPANT ID I	1.1	1.1	1.1	1.1	1 1	1.1	1.1	1.1	- 1
PANTICIPAINT ID I			1 1	1 1	1 1	1 1		1 1	- 1

# ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK DAILY FORM complete per Tier of activity AND if research samples are collected Page 1 of 2

DAILY TREATMENT (complete every line):						
DATE OF ASSESSMENT (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]  Record the worst value between 00:00 to 24:00 on day of assessment (if Not Available write 'N/K'):						
Is the patient in a high-level care area i.e. admitted to ICU/ITU/IMC/HDU ☐YES ☐NO ☐N/K						
Highest Temperature: [_ ][]•[] °C						
Any Supplemental Oxygen SES NO N/K FiO <sub>2</sub> (0.21-1.0) [ ].[ ] or [ ][ ]% or [ ][ ] L/min (highest)						
Oxygen saturation Section No No Note of the section						
AVPU Alert[] Verbal[] Pain [] Unresponsive[] or $\square N/K$ Glasgow Coma Score (GCS / 15) [][] or $\square N/K$						
Is the patient currently receiving, or has received (from 00:00 to 24:00) on day of assessment:  Non-invasive respiratory support (e.g. NIV, BIPAP, CPAP)? □YES □NO □N/K Invasive ventilation? □YES □NO □N/K  High-flow nasal canula? □YES □NO □N/K ECLS/ECMO? □YES □NO □N/K						
DAILY LABORATORY RESULTS						
Record the values of laboratory results taken between 00:00 to 24:00 on day of assessment (if Not Available write 'N/K, if multiple record the values for the blood draw taken closest to midday'):						
Done □YES □NO □N/K Haemoglobin □g/L or □g/dL						
Done □YES □NO □N/K WBC count □x10 <sup>9</sup> /L or □x10 <sup>3</sup> /μL						
Done   Output  Done Output  O						
Done   One						
Done □YES □NO □N/K Platelets □x10 <sup>9</sup> /L or □x10 <sup>3</sup> /μL Done □YES □NO □N/K APTT/APTR						
Done □YES □NO □N/K PT seconds <i>or</i> Done □YES □NO □N/K INR						
Done TYES TNO TN/K ESR mm/hr						
Done □YES □NO □N/K Ferritin □μg/L <i>or</i> □ ng/mL						
Done TYES NO N/K ALT/SGPT U/L						
Done □YES □NO □N/K Total Bilirubin□μmol/L <i>or</i> □mg/dL						
Done SYES SNO SN/K AST/SGOTU/L						
Done □YES □NO □N/K Glucose □mmol/L or □mg/dL						
Done □YES □NO □N/K Blood Urea Nitrogen (urea) □ □mmol/L or □mg/dL						
Done □YES □NO □N/K Lactate □ □ □mmol/L or □mg/dL						
Done   YES   NO   N/K LDH  ][].[].U/L						
Done TYES THO THE Constining Kinase (CPK) [][][].[]_U/L						
Done TYES THO THE TWO THE CONTROL TO THE THE TWO THE TWO THE THE TWO T						
Done TYES TNO TN/K Sodium Tmmol/L or TmEq/L						
Done TYES TNO TN/K Proceeds the pin [ 1] 1   1   1   1   1   1   1   1   1						
Done □YES □NO □N/K Procalcitonin [][].[]ng/mL           Done □YES □NO □N/K CRP [][].[] mg/L						
Done TYES TO TO N/K eGFR mL/min/1.73 m <sup>2</sup> OCKD-EPI OMDRD OCG						
Most recent HbA1c □ N/K date of HbA1c [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]						



PARTICIPANT ID I	1.1	1.1	1.1	1.1	I I	1.1	1.1	1.1	- 1
FAITHCIFAITH	1 1	1 1	1 1					1 1	

### DAILY FORM complete per Tier of activity AND if research samples are collected Page 2 of 2

ISARIC CCP-UK RESEARCH SAMPLES						
Was a biological sample taken for research on this day?	□YES □NO					
If yes, please record the KIT number:	KIT NUMBER [_C_] [_C_] [_P_] [] [][][]					



PARTICIPANT ID I	1.1	1.1	1.1	1.1	I I	1.1	1.1	1.1	- 1
FAITHCIFAITH	1 1	1 1	1 1					1 1	

### **ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK**

OUTCOME FORM Page 1 of 5

PATHOGEN DIAGNOSIS SUMMARY	
Was pathogen testing done during this illness episode? □YES □NO □N/K	
NB Should be a YES as this is key eligibility criteria	
Remember to record the detail of the COVID-19 / SARS2-CoV-2 which may have been done in the community	
If Yes:	

Section 1: Respiratory virus PCR or antigen tests (NOT serology/antibody tests)

	Tested and POSITIVE	Tested and NEGATIVE	<b>NOT TESTED</b>
	(please tick)	(Please tick)	(please tick)
COVID-19 / SARS-CoV-2	Yes□	<u></u>	
Influenza virus	Yes □		
NB: Please do not enter Haemophilus influenza or	Please confirm type:	<u>u</u>	<u>=</u>
parainfluenza virus here – enter them under "other" below	□ A/H3N2 □ A/H1N1pdm09 □ A/H7N9		
	☐ A not typed other A ☐		
	☐ B not typed		
	☐ Other type (specify):		
Respiratory syncytial virus	Yes □	П	
(RSV)			
<u>Adenovirus</u>	Yes □	□	
<u>Other</u>	Yes ☐ please specify :		



DARTICIDANIT ID I							 
PARTICIPANT ID I	11	11	11	11	l I	11	l I

OUTCOME FORM Page 2 of 5

#### **PATHOGEN TESTING DETAILS**

Section 2: Please record the details of all tests carried out during this illness episode below (including the details of the tests indicated above).

\*Please include tests relating to: Respiratory, virus, bacteria, fungi and other pathogens.

		If "Obtained: positive" (free text, or	
	Select one:	Organism	Date sample obtained
Nasal and/ or	☐ Obtained: positive		
throat swab	☐ Obtained: negative		
	☐ Not obtained		
Blood culture	☐ Obtained: positive		
	☐ Obtained: negative		
	□ Not obtained		
Sputum	☐ Obtained: positive		
	☐ Obtained: negative		
	□ Not obtained		
Deep respiratory	☐ Obtained: positive		
sample (BAL/ETA)	☐ Obtained: negative		
	□ Not obtained		
Urine	☐ Obtained: positive		
	☐ Obtained: negative		
	□ Not obtained		
Cerebrospinal fluid	☐ Obtained: positive		
(CSF)	☐ Obtained: negative		
	□ Not obtained		
Faeces (stool)	☐Obtained: positive		
	☐ Obtained: negative		
	□ Not obtained		

If multiple negative result are obtained for a given sample (with no positives) this is recorded once only as "Obtained:negative"

Please record below any other samples that gave a POSITIVE result:

Sample type	Organism	Date sample obtained
☐ Abdominopelvic		
■ Vascular access tip		
☐ Catheter urine		
☐ Abscess aspirate		
□ Other		
□ Abdominopelvic		
☐ Vascular access tip		
☐ Catheter urine		
☐ Abscess aspirate		
☐ Other		



PARTICIPANT ID I	1.1	1.1	1.1	1.1	1 1	1.1	1.1	1.1	
PARTICIPANTIDI	1 1	1 1	1 1	1 1	1 1	1 1	1 1	1 1	

OUTCOME FORM Page 3 of 5

MEDICATION: While hospitalised or at discharge, were any of the following administered?
Antiviral agent? ☐YES ☐NO ☐ N/K If YES, tick all the apply: ORibavirin OLopinavir/Ritonavir OInterferon alpha
OInterferon beta OChloroquine / Hydroxychloroquine OOseltamivir (Tamiflu®) OZanamivir
OOther antiviral
ORemdesivir If YES: first dose: [D][D]/[M][M]/[Y][Y] and last dose [D][D]/[M][M]/[Y][Y]
O IL6 inhibitor IF YES which ☐ Tocilizumab ☐ Other IL6 inhibitor
<b>IL6 inhibitor</b> first dose: [_D_][_D_]/[_M_][_M_]/[_Y_][_Y_] and last dose [_D_][_D_]/[_M_][_M_]/[_Y_][_Y_]
Antibiotic?
Corticosteroid? ☐YES ☐NO ☐N/K If YES, Route: ☐ Oral ☐ Intravenous ☐ Inhaled
If YES, please provide type / name and maximum daily dose:
Dexamethasone 6mg once per day (od)? ☐YES ☐NO ☐N/K If YES, Route: ☐ Oral ☐ Intravenous
Other Dexamethasone dosemg
Other Dexamethasone other frequency OBD OTDS OQDS OOther
Dexamethasone Route:  Oral Intravenous
Antifungal agent? ☐YES ☐NO ☐N/K If YES: which
Off-label / Compassionate Use medications? □YES □NO □N/K If YES: which
Interleukin inhibitors □YES □NO □N/K If YES: which
Convalescent plasma □YES □NO □N/K
TREATMENT: At ANY time during hospitalisation, did the patient receive/undergo:
ICU or High Dependency Unit admission? ☐YES ☐NO ☐N/K If YES, total duration:days <b>O</b> still in ICU/HDU
If NO, □Not Indicated □Not appropriate*
(*Advanced care plan/discussion documented in notes regarding not for escalation of care beyond ward)
Date of ICU/HDU admission: D ][ D ]/[ M ][ M ]/[ 2 ][ 0 ][ Y ][ Y ]
ICU/HDU discharge date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □N/K  Any Oxygen therapy? □YES □NO □N/K High-flow nasal canula? □YES □NO □N/K
Non-invasive ventilation? (e.g. BIPAP, CPAP)
Invasive ventilation (Any intubation)?    YES NO N/K  If YES, total duration:days O still on
Prone Ventilation?   YES NO N/K  NOTE: NO N/K
Inhaled Nitric Oxide? □YES □NO □N/K  Tracheostomy inserted? □YES □NO □N/K
Extracorporeal (ECMO) support?
Renal replacement therapy (RRT) or dialysis?   YES   NO   N/K If YES, total duration:days   O still on
Renal replacement therapy (RRT) or dialysis?   YES  NO  N/K If YES, total duration:days  O still on  Inotropes/vasopressors?   YES  NO  N/K If YES, total duration:days  O still on



PARTICIPANT ID I	1.1	1.1	1.1	1.1	1 1	1.1	1.1	1.1	- 1
PANTICIPAINT ID I			1 1	1 1	1 1	1 1		1 1	- 1

OUTCOME FORM Page 4 of 5

COMPLICATIONS: At any time during hospitalisation did the patient experience:										
Viral pneumonia	□YES	□по	□n/ĸ	Cardiac ischemia	□YES	□по	□n/k			
Bacterial pneumonia	□YES	□по	□n/k	Cardiac arrest	□YES	□по	□n/k			
Acute Respiratory Distress Syndrome	□YES	□no	□n/K	Bacteraemia	□YES	□no	□n/k			
Cryptogenic organizing pneumonia (COP)	□YES	□no	□n/K	Coagulation disorder / Disseminated Intravascular Coagulation	□YES	□no	□n/k			
Pneumothorax	□YES	□ио	□n/k	Deep vein thrombosis	□YES	□no	□n/k			
Pleural effusion	□YES	□ио	□n/k	Pulmonary thromboembolism	□YES	□ио	□n/k			
Bronchiolitis	□YES	□ио	□n/k	Anaemia	□YES	□ио	□n/k			
Meningitis / Encephalitis	□YES	□ио	□n/k	Rhabdomyolysis / Myositis	□YES	□ио	□n/k			
Seizure	□YES	□no	□n/K	Acute renal injury/acute renal failure	□YES	□no	□n/k			
Stroke / Cerebrovascular accident	□YES	□no	□n/K	Gastrointestinal haemorrhage	□YES	□no	□n/k			
Other neurological complication	□YES	□no	□n/K	Pancreatitis	□YES	□no	□n/k			
Congestive heart failure	□YES	□по	□n/k	Liver dysfunction	□YES	□по	□n/k			
Endocarditis	□YES	□по	□n/ĸ	Hyperglycaemia	□YES	□по	□n/k			
Myocarditis/Pericarditis	□YES	□по	□n/ĸ	Hypoglycaemia	□YES	□по	□n/k			
Cardiomyopathy	□YES	□по	□n/ĸ	Other, if yes specify below	□YES	□по	□n/k			
Cardiac arrhythmia	□YES	□no	□n/k	Other:						

STUDY PARTICIPATION						
Is / Has the participant being/ been recruited to a trial or multi-centre study during the period of their current illness (including						
initiation in the community and hospital)? $\square$ YES $\square$ NO						
IF YES , specify						
Name of study						
Study Participant ID						
Add another study? ☐ YES ☐ NO						
IF YES , specify						
Name of study						
Study Participant ID						
Add another study? ☐ YES ☐ NO						
IF YES , specify						
Name of study						
Study Participant ID						





OUTCOME FORM Page 5 of 5

INTERIM OUTCOME: DAY 28			
Outcome:   Discharged alive expected	to survive		
☐ Hospitalisation = Remains	in Hospital ≥ Day 28 after symptom	n onset	
OR	oing health care needs relating to the		
reasc	cally fit for discharge (COVID-19 res on (e.g. awaiting suitable care in cor or mental health facility)	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
☐ Transfer to other facility	☐ Palliative discharge	☐ Death	□ N/K
Outcome date: [_D_][_D_]/[_M_][_M_]	/[_2_][_0_][_Y_][_Y_]		
If Discharged alive:			
Ability to self-care at discharge versus b	efore illness:   Same as before illness	☐ Worse ☐ Bette	er □ N/K
If Discharged alive: Post-discharge treat Oxygen therapy? □			
If Transferred: Facility name:			□ N/K
If Transferred: Is the transfer facility a st	:udy site? ☐ YES ☐ NO ☐ N/K		
If a Study Site: Participant ID # at new fa	cility:   Same as above		
☐ Different: [][][][]	- [][][] □n/ĸ		
FINAL OUTCOME (If status has change	ed since day 28)		
Outcome:			
☐ Discharged alive expected to survive	☐ Palliative discharge ☐ Death	h 🔲 Transfer t	o other facility
Outcome date : [_D_][_D_]/[_M_][_M_]	/[_2_][_0_][_Y_][_Y_] □ N/K		
If Discharged alive:			
Ability to self-care at discharge versus b	efore illness:   Same as before illness	☐ Worse ☐ Bette	er □ N/K
If Discharged alive: Post-discharge treat Oxygen therapy? ☐			
If Transferred: Facility name:			□ <b>n</b> /K
If Transferred: Is the transfer facility a st	udy site? ☐ YES ☐ NO ☐ N/K		
If a Study Site: Participant ID # at new fa ☐ Different: [ ][ ][ ][ ][ ]	•		



PARTICIPANT ID I	11	11	11		11	11	11	- 1

# ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK WITHDRAWAL FORM Page 1 of 1

WITHDRAWAL
Date of withdrawal:D_](_D_]/[_M_](_M_]/[_2_](_0_](_Y_](_Y_)
Type of withdrawal: ☐ Withdrawal from samples only ☐ Other Please specify:
Reason for withdrawal: